spacer
home > ict > spring 2006 > everybody wins
PUBLICATIONS
International Clinical Trials

Everybody Wins

Providing sites with the communication tools to engage and retain patients is crucial contend Janet Jones at Kendle and Val Lyness at ICR, as they explore holistic approaches to patient-centric recruitment and retention

“What’s in it for me?” Nine times out of 10, it’s the first thing a patient will think about when considering whether or not to participate in a clinical study. As an industry, we’re well aware of this, but are we giving patients the right answers? Are we approaching patient recruitment and retention in the best way possible?

WHAT HAPPENS WHEN THE SITE’S DATABASE IS EXHAUSTED?

There are several steps that can be considered when a site’s database has become exhausted, such as referrals from colleagues, the involvement of advocacy or patient support groups, community outreach with flyers and mailings and direct-to-patient communications. Recruitment planning needs to be considered at several levels ranging from providing siteby- site recruitment plans through to conducting a full directto- patient media campaign.

Sites need to be encouraged to start thinking about the next contingency plan early in the process, not when the failure to recruit has become a major issue. CRAs and the project team can help the sites to develop specific recruitment plans, and to constantly think about the next step and how to overcome recruitment barriers.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
5
     

There are no comments in regards to this article.

spacer

Dr Janet Jones, Director of Global Patient Access and Retention, joined Kendle in 2000 and has overall responsibility for Kendle’s integrated patient recruitment and retention programs. With more than 20 years’ experience in clinical research, she has gained a wealth of industry expertise as a CRA, lead CRA and project manager. Janet is a widely-published molecular geneticist and patient recruitment and retention expert, with a doctorate in molecular biology.

Val Lyness is a leading figure within the Institute of Clinical Research (ICR) having been Chairman of the Board from 1997 until 2000. She is an active member of the ICR Advisory Group that provides guidance to ICR on consultations and current issues. As one of the longest-serving members, she is now an Honorary Fellow of the ICR with more than 20 years’ experience as a clinical research professional.

spacer
Janet Jones
spacer
spacer
spacer
Val Lyness
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma enters into Development and Manufacturing Agreement with Synklino

Vilnius, Lithuania, and Copenhagen, Denmark – December 18th 2019 – Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Synklino, a company active in developing a therapeutic protein based therapy as treatment for cytomegalovirus (CMV) infection, announced today that they entered into a Development and Manufacturing Agreement for the recombinant fusion protein SYNx, which Synklino aims to bring into clinical trials.
More info >>

White Papers

Clinical Trial Disclosure Management: Build vs. Buy

TrialScope

Because software development is our core competency, TrialScope continues to make a significant investment in our technology. We employ agile methodologies to ensure that we can maintain a continuing level of responsiveness as disclosure requirements evolve across registries and regions.
More info >>

 
Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement